Cargando…

P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY

Detalles Bibliográficos
Autores principales:	Hutchings, Martin, Carlo-Stella, Carmelo, Morschhauser, Franck, Dickinson, Michael, Bachy, Emmanuel, Cartron, Guillaume, Khan, Cyrus, Tani, Monica, Martinez-Lopez, Joaquín, Bartlett, Nancy L., Salar, Antonio, Brody, Joshua, Leppa, Sirpa, Baumlin, Pauline, Lundberg, Linda, Relf, James, Xie, Yuying, Bottos, Alessia, Humphrey, Kathryn, Falchi, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430978/ http://dx.doi.org/10.1097/01.HS9.0000971412.45898.1a

Ejemplares similares

P1210: IMMUNE CORRELATES OF RESPONSE TO GLOFITAMAB: BIOMARKER FINDINGS FROM A PIVOTAL PHASE II EXPANSION STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Piccione, E. C., et al.
Publicado: (2022)

Glofitamab: First Approval
por: Shirley, Matt
Publicado: (2023)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

PReS13-SPK-1129: Biologic therapies in SLE
por: Isenberg, DA
Publicado: (2013)

1129. Targeted Voriconazole Prophylaxis in Heart Transplantation Recipients
por: Lin, Michael, et al.
Publicado: (2018)

1129. Outpatient Prescribing During the COVID-19 Pandemic
por: Moorthy, Ganga, et al.
Publicado: (2021)

1129. Optimizing Feedback Strategies on the Infectious Diseases Inpatient Service
por: Clark, Eva, et al.
Publicado: (2020)

P1129: ACALABRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): RESULTS OF A PHASE 2, MULTICENTER, OPEN-LABEL TRIAL
por: Strati, P., et al.
Publicado: (2022)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
por: Rentsch, Vera, et al.
Publicado: (2022)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
por: Rejeski, K., et al.
Publicado: (2022)

1129 Varicella in Belgium: a National One year Prospective Survey
por: Blumental, Sophie, et al.
Publicado: (2014)

1129. Assessment of Nurses’ Views on Antimicrobial Stewardship at a Pediatric Hospital
por: Yu, Diana, et al.
Publicado: (2019)

ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV
por: Strati, Paolo, et al.
Publicado: (2023)

P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY
por: Derigs, P., et al.
Publicado: (2022)

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma
por: Bröske, Ann-Marie E., et al.
Publicado: (2022)

Epidemiological Investigation of Pediatric Fractures—A Retrospective Cohort Study of 1129 Patients
por: Xiao, Xiaoliang, et al.
Publicado: (2023)

Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma
por: Heini, Alexander D., et al.
Publicado: (2022)

Evaluation of sleep disorder in orthopedic trauma patients: a retrospective analysis of 1129 cases
por: Yang, Hai, et al.
Publicado: (2021)

P1197: AXICABTAGENE CILOLEUCEL (AXI-CEL) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): OUTCOMES OF THE PHASE 2 ZUMA-14 STUDY
por: Strati, P., et al.
Publicado: (2022)

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
por: Hutchings, Martin, et al.
Publicado: (2021)

PB2100: MANAGEMENT OF RELAPSED / REFRACTORY (R/R) B-CELL NON HODGKIN LYMPHOMA (B-NHL) WITH ANTI-CD20XCD3 BISPECIFIC ANTIBODY GLOFITAMAB. A SINGLE CENTER EXPERIENCE.
por: Giatra, C., et al.
Publicado: (2022)

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
por: Abramson, Jeremy S., et al.
Publicado: (2022)

P1179: PROGNOSIS OF PATIENTS WITH AGGRESSIVE REFRACTORY B-NHL TREATED WITH GLOFITAMAB IN REAL CLINICAL PRACTICE
por: Fedorova, Liudmila, et al.
Publicado: (2023)

P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY
por: Minson, Adrian, et al.
Publicado: (2023)

S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
por: Sureda, Anna, et al.
Publicado: (2023)

S227: INITIAL SAFETY DATA FROM THE PHASE 3 POLAR BEAR TRIAL IN ELDERLY OR FRAIL PATIENTS WITH DIFFUSE LARGE CELL LYMPHOMA, COMPARING R-POLA-MINI-CHP AND R-MINI-CHOP
por: Jerkeman, Mats, et al.
Publicado: (2023)

Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting
por: Wang, Chaoyu, et al.
Publicado: (2023)

P1710: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE TREATMENT FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PATIENT-REPORTED OUTCOMES (PRO) FROM THE PHASE 2 PILOT STUDY
por: Gordon, L. I., et al.
Publicado: (2022)

P1157: PHASE II STUDY OF GLOFITAMAB, POSELTINIB AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE B CELL LYMPHOMAS
por: Min Byun, Ja, et al.
Publicado: (2023)

Curated single cell multimodal landmark datasets for R/Bioconductor
por: Eckenrode, Kelly B., et al.
Publicado: (2023)

P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)
por: Munoz, Javier, et al.
Publicado: (2023)

Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL
por: Perez, Ariel, et al.
Publicado: (2022)

SG-APSIC1129: Long-term effect of a bundled care program in reducing central-line–associated bloodstream infections
por: Liu, Yingchieh, et al.
Publicado: (2023)

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience
por: Trando, Aaron, et al.
Publicado: (2023)

R-spondin signaling as a pivotal regulator of tissue development and homeostasis
por: Nagano, Kenichi
Publicado: (2019)

Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody
por: Messori, Andrea, et al.
Publicado: (2022)

J.R.R. Tolkien : una biografía /
por: Carpenter, Humphrey
Publicado: (1990)

J.R.R. Tolkien : una biografía
por: Carpenter, Humphrey
Publicado: (2002)

P1744: ACCURACY OF PREDICTING LONG-TERM SURVIVAL OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPIES IN LARGE B-CELL LYMPHOMA (LBCL)
por: Verburg-Baltussen, E. J., et al.
Publicado: (2022)

Testicular Diffuse Large B-Cell Lymphoma—Clinical, Molecular, and Immunological Features
por: Pollari, Marjukka, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o3l60mpgpubakvpnd490vekhst